PALB2 and non-small cell lung carcinoma: The OAK and POPLAR study cohort of NSCLC patients showed that there was no difference in overall survival (OS) (HR = 1.1, p = 0.75) between PALB2 mutation (10.38 months) and PALB2wt (11.07 months).